The FDA Is Signaling a Major Shift in How We Think About Evidence and Approval

In a recent New England Journal of Medicine article, FDA officials Vinay Prasad and Martin Makary introduced the Plausible Mechanism Pathway—a regulatory approach designed to accelerate access to personalized therapies when traditional randomized trials aren’t feasible.

This pathway focuses on therapies for conditions with:

• A known biologic cause (e.g., genetic conditions with a specific molecular or cellular abnormality)
• A well-characterized natural history, such as progressive damage when treatment options are exhausted
• An investigational therapy that targets the underlying biological alteration
• Evidence of successful target engagement in preclinical models
• Demonstrated improvement in clinical outcomes or disease course

Importantly, the FDA may consider patients as their own control and, while initially focused on rare genetic diseases, this approach could extend to common diseases with unmet needs.

What does this mean for us?

It’s not just a regulatory update—it’s a paradigm shift. At CLD, we’re already strategizing how to equip Medical Affairs and Sales teams with the knowledge and tools they’ll need to thrive in this new era of personalized medicine.

The future of clinical evidence is evolving. Are you ready?